Group 1 - The core point of the news is that southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 1.466 million shares on November 13, 2025, with a total net increase of 4.3525 million shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 13.1125 million shares [1] - As of now, southbound funds hold 1.448 billion shares of Jinxin Reproductive Medicine, accounting for 52.5% of the company's issued ordinary shares [1] Group 2 - The company, Jinxin Reproductive Medicine, is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-12 | 14.46 Z | -437.50万 | -0.30% | | 2025-11-11 | 14.51亿 | -99.65万 | -0.07% | | 2025-11-10 | 14.52亿 | 1010.85万 | 0.70% | | 2025-11-07 | 14.42 乙 | -185.05万 | -0.13% | | 2025-11-06 | 14.44亿 | 202.25万 | 0.14% | 证券之星消息，11月12日南向资金减持437.5万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持490.9万股。近20个交易日中，获南向资金增持的有11天，累计净增持2287.7 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.46亿股，占公司已发行普通股的52.44%。 锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 錦欣生殖醫療集團有限公司* Jinxin Fertility Group Limited * 1951 進一步延遲寄發通函 茲提述錦欣生殖醫療集團有限公司*（「本公司」）日期為2025年9月25日的公告，內容有關 （其中包括）建議採納2025年股份計劃及有條件向本公司董事及高級管理層授出2025年股 份計劃項下的購股權及受限制股份，及本公司日期為2025年10月20日的公告，內容有關 延遲寄發通函（統稱「該等公告」）。除另有界定者外，本公告所用詞彙與該等公告所界定 者具有相同涵義。 誠如該等公告所披露，一份載有（其中包括）建議採納2025年股份計劃及有條件向董陽先 生授出購股權連同其項下擬進行之其他交易的進一步詳情以及召開股東特別大會的通告 的通函（「該通函」）將寄發予股東。 由於本公司需要額外時間編製及落實載入該通函的若干資料，預期寄發該通函的日期將 推遲至2025年11月25日或之前。 ...

Core Insights - The 8th China International Import Expo (CIIE 2025) showcased over 2,800 enterprises from more than 100 countries, with a significant focus on medical technology innovations [2] - Three key trends emerged in the medical technology sector: higher global innovation density, stronger system collaboration, and deeper participation from domestic manufacturers [2] - Notable companies highlighted include Boston Scientific, Medtronic, Alcon, GE, Siemens, Intuitive Surgical, and Yuanhua Intelligent, covering a wide range of medical technologies [2] Group 1: Boston Scientific - Boston Scientific presented over 80 minimally invasive products, with six new products making their debut, including the FARAWAVE NAV catheter and AdVance XP sling [4][6] - Key innovations focus on integrated solutions for atrial fibrillation treatment, male stress urinary incontinence, and carotid artery reconstruction safety [6][7] - The company's diverse portfolio reflects a dual drive of global innovation and local manufacturing [7] Group 2: Medtronic - Medtronic showcased over 100 innovative technologies, emphasizing a systematic approach to future surgery and intelligent medical solutions [9][10] - The AiBLE™ digital innovation ecosystem was highlighted, integrating navigation, robotics, imaging, and monitoring for enhanced surgical precision [9] - Collaborations with local partners aim to enhance the adoption of smart spine surgery and laser ablation techniques [10] Group 3: Alcon - Alcon celebrated its 30th anniversary in China, presenting innovations across the entire eye health spectrum, including three new products [11][15] - Collaborations with local institutions aim to accelerate the implementation of innovative solutions in China [15] - The company announced plans for local production of its Wavelight® excimer laser surgery equipment, enhancing the domestic supply chain [15] Group 4: Intuitive Surgical - Intuitive Surgical, a consistent participant, showcased its surgical robots and digital innovations, emphasizing a patient-first approach [19] - The Da Vinci surgical system has served over 810,000 patients in China, with new systems entering the regulatory approval process [19] - The company is building a comprehensive ecosystem that integrates diagnosis, treatment, and training [20] Group 5: GE Healthcare - GE Healthcare introduced nearly 40 innovative products, including 18 new launches and 9 global debuts, focusing on advanced imaging technologies [29][31] - The Expert X quantum CT system and MR-PET technology were highlighted for their capabilities in cardiac imaging and metabolic assessment [31] Group 6: Siemens Healthineers - Siemens Healthineers emphasized its commitment to precision diagnosis and treatment for major diseases, showcasing the ARTIS icono ceiling Xpand system [35][37] - Innovations in CT and AI cardiovascular ultrasound technologies aim to enhance diagnostic efficiency and safety [37] Group 7: Abbott - Abbott presented over ten innovative products, including the AVEIR™ DR dual-chamber leadless pacemaker, addressing chronic disease management [21][24] - The company’s offerings span multiple health management areas, including cardiovascular and diabetes care [27] Group 8: Yuanhua Intelligent - Yuanhua Intelligent introduced the world's first "five-in-one" orthopedic surgical robot system, enhancing the digital workflow in orthopedic surgeries [25][28] - The system integrates various surgical procedures, marking a significant advancement in the field [28] Group 9: Other Notable Companies - Companies like Edwards Lifesciences, Johnson & Johnson, and others showcased innovative solutions in heart valve repair, minimally invasive surgery, and advanced imaging technologies [42][45][46] - The overall trend indicates a shift towards integrated systems and collaborative innovations across the medical technology landscape [66][67]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 7.45 million shares on November 3, 2025, marking a decrease of 0.52% [1][2] - Over the past five trading days, there have been four days of net reductions in holdings, totaling 8.89 million shares [1][2] - In the last 20 trading days, there were 11 days of net increases in holdings, amounting to a total of 15.63 million shares [1][2] Group 2 - As of now, southbound funds hold 1.436 billion shares of Jinxin Reproductive Medicine, which represents 52.07% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services, along with various reproductive and medical services [2] - The company operates mainly in China and the United States, offering auxiliary reproductive services, management services, and sales of medical consumables and equipment [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Core Insights - The China International Import Expo (CIIE) serves as a vital platform for global innovation to enter the Chinese market, with companies like Edwards Lifesciences leveraging it to enhance local partnerships and accelerate the clinical application of innovative medical technologies [1][2] - Edwards has witnessed significant growth in the Chinese medical industry over the past 25 years, benefiting from an improved business environment and innovative regulatory breakthroughs [1] - The company plans to expand its local collaboration network and deepen partnerships with clinical experts to enhance the treatment of structural heart diseases in China [1] Company Highlights - Edwards Lifesciences has successfully transitioned multiple innovative products from exhibition to clinical application, including the INSPIRIS RESILIA valve launched in 2021 and the SAPIEN3 Ultra RESILIA valve, which debuted at the 2023 CIIE [1] - The MITRIS RESILIA valve was officially launched in China in April 2023, showcasing the rapid commercialization of products introduced at the expo [1] - The PASCAL Precision transcatheter valve repair system made its debut at the CIIE after being launched in Hong Kong [1] Other Company Activities - This year marks the sixth consecutive participation of Edwards at the CIIE, where it showcases a full range of cutting-edge products and treatment solutions, including an interactive experience area for participants [2] - AstraZeneca, Novo Nordisk, and Intuitive Surgical are also notable participants, with AstraZeneca planning to announce a new production expansion plan and showcasing over 40 innovative drugs [2] - Novo Nordisk is focusing on obesity management with an immersive experience space, highlighting the importance of public awareness regarding obesity [2] Product Innovations - Novo Nordisk will present advancements in its "semaglutide family" of products, including the approval of new indications for chronic kidney disease and the introduction of oral formulations [3] - Intuitive Surgical will showcase its da Vinci surgical robots, emphasizing its commitment to innovation in medical technology and the Chinese market [3] - The company aims to build a comprehensive training system for hospitals and doctors to enhance their skills in robotic surgery [3]

Core Points - Jinxin Fertility (01951) announced the resignation of Ms. Zhai Yangyang as co-company secretary and Ms. Wu Xiuwai as co-company secretary and authorized representative under the Hong Kong Stock Exchange Listing Rules effective October 31, 2025 [1] - Ms. Zhai resigned to pursue personal career development, while Ms. Wu resigned due to other work arrangements [1] - Ms. Zhong Manna has been appointed as the company secretary and authorized representative effective October 31, 2025 [1]

Core Points - Jinxin Fertility (01951) announced the resignation of two co-secretaries, Zhai Yangyang and Wu Xiuwai, effective October 31, 2025 [1] - Zhai Yangyang resigned to pursue personal career development, while Wu Xiuwai resigned due to other work arrangements [1] - Zhong Manna has been appointed as the new company secretary and authorized representative effective October 31, 2025 [1]

Core Viewpoint - Jinxin Reproductive (01951.HK) announced the resignation of two co-secretaries and the appointment of a new company secretary effective October 31, 2025 [1] Group 1 - Zhai Yangyang resigned as co-secretary for personal career development reasons [1] - Wu Xiuwai resigned as co-secretary and authorized representative due to other work arrangements [1] - Zhong Manna has been appointed as the new company secretary and authorized representative, bringing over 25 years of experience in corporate governance and compliance [1]